☆ 4.7 Letter

Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2

LEUKEMIA (2014)

期刊

LEUKEMIA

卷 28, 期 9, 页码 1918-1922

出版社

NATURE PUBLISHING GROUP

DOI: 10.1038/leu.2014.152

关键词

类别

Oncology Hematology

资金

Austrian Science Fund (FWF) [P 24295] Funding Source: researchfish
Austrian Science Fund (FWF) [P24295] Funding Source: Austrian Science Fund (FWF)
Austrian Science Fund FWF [P 24295] Funding Source: Medline
NCI NIH HHS [R01 CA151949, P30 CA008748] Funding Source: Medline

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

主要评分

4.7

评分不足

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

A novel imatinib-upregulated long noncoding RNA plays a critical role in inhibition of tumor growth induced by Abl oncogenes

Yun Ma, Guijie Guo, Tingting Li, Faxin Wen, Jianling Yang, Biao Chen, Xuefei Wang, Ji-Long Chen

Summary: The study reveals that lncRNA-IUR1 plays an inhibitory role in Abl-mediated cellular transformation, providing new insights into the molecular mechanisms underlying Abl-induced leukemogenesis.

MOLECULAR CANCER (2022)

添加到收藏夹

Article Oncology

Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A

Yun Xu, Ziting Wang, Lei Zhang, Congying Gao, Fahui Li, Xueming Li, Yu Ke, Hong-Min Liu, Zhenbo Hu, Liuya Wei, Zhe-Sheng Chen

Summary: The compound JOA can inhibit the proliferation of chronic myeloid leukemia cells, including those with the BCR-ABL-T315I mutation, and induce cell differentiation. This effect may be mediated by the inhibition of the BCR-ABL/c-MYC signaling pathway. JOA shows potential as a lead compound for overcoming imatinib resistance in CML therapy.

JOURNAL OF CANCER (2023)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation

Haixia Liu, Xinyu Ding, Linyi Liu, Qianglong Mi, Quanju Zhao, Yubao Shao, Chaowei Ren, Jinju Chen, Ying Kong, Xing Qiu, Nicola Elvassore, Xiaobao Yang, Qianqian Yin, Biao Jiang

Summary: Protein degradation through CRBN-recruiting PROTACs has shown promising potential in targeting oncogenic fusion protein BCR-ABL, providing a potential therapeutic strategy for chronic myeloid leukemia.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Oncology

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia

Lioba Schoenfeld, Jenny Rinke, Anna Hinze, Saskia N. Nagel, Vivien Schaefer, Thomas Schenk, Christian Fabisch, Tim H. Bruemmendorf, Andreas Burchert, Philipp le Coutre, Stefan W. Krause, Susanne Saussele, Fatemeh Safizadeh, Markus Pfirrmann, Andreas Hochhaus, Thomas Ernst

Summary: Gene mutations independent of BCR::ABL1, especially in epigenetic modifier genes, are common in newly diagnosed patients with chronic myeloid leukemia in chronic phase. Specifically, ASXL1 mutations have been found to be the most commonly affected. These mutations are associated with less favorable molecular response to nilotinib treatment, and patients carrying ASXL1 mutations are typically younger and more frequently classified as high risk, suggesting a central role of clonal evolution associated with ASXL1 mutations in CML pathogenesis.

LEUKEMIA (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)

Tingting Lu, Jiangyan Cao, Fengming Zou, Xixiang Li, Aoli Wang, Wenliang Wang, Huamin Liang, Qingwang Liu, Chen Hu, Cheng Chen, Zhenquan Hu, Wenchao Wang, Lili Li, Jian Ge, Yang Shen, Tao Ren, Jing Liu, Ruixiang Xia, Qingsong Liu

Summary: CHMFL-48 is a novel type II kinase inhibitor that potently inhibits the wild-type BCR-ABL kinase and a panel of imatinib-resistant mutants. This drug shows strong inhibitory activity in a cellular context, blocking autophosphorylation of BCR-ABL kinase, affecting downstream signaling mediators, and inducing cell cycle progression blockade and apoptosis.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

A novel fusion circular RNA F-circBA1 derived from the BCR-ABL fusion gene displayed an oncogenic role in chronic myeloid leukemia cells

Yuan Tan, Zhenglan Huang, Xin Wang, Hongdan Dai, Guoyun Jiang, Wenli Feng

Summary: This study identified a novel fusion circRNA (F-circBA1) originating from BCR-ABL, which is mainly localized in the cytoplasm and plays an oncogenic role in CML cells.

BIOENGINEERED (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase

Elena V. Koroleva, Yuri V. Kornoushenko, Anna D. Karpenko, Ivan P. Bosko, Julia V. Siniutsich, Zhanna V. Ignatovich, Alexander M. Andrianov

Summary: An integrated computational approach was used to identify potential inhibitors of Bcr-Abl tyrosine kinase, an enzyme involved in chronic myeloid leukemia. Five compounds were found to effectively block the enzyme activity and exhibit high binding affinity comparable to FDA-approved kinase inhibitors. These compounds may serve as good scaffolds for the design of novel anticancer agents.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co-existence in Philadelphia positive CML patients

Nasir Ahmad, Saima Qayum, Abid Jamee, Asif Ali, Sami Siraj, Johar Ali, Yasar Mehmood Yousafzai

Summary: This study found that JAK2-V617F mutation in BCR-ABL positive CML patients is rare, and treatment with TKI may not reduce the burden of JAK2 mutation.

PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)

添加到收藏夹

Article Medicine, Research & Experimental

circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation

Jianming Wang, Yang Liang, Yuefeng Qin, Guoyun Jiang, Yuhang Peng, Wenli Feng

Summary: This study uncovers that circCRKL is specifically expressed and regulates the expression level of BCR-ABL via decoying miR-877-5p in BCR-ABL(+) cells. The findings suggest that targeting circCRKL along with imatinib treatment could be a potential therapeutic strategy for CML patients.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition

Congying Gao, Lei Zhang, Yun Xu, Xiangyu Ma, Peilei Chen, Zhe-Sheng Chen, Liuya Wei

Summary: In this study, the potent histone deacetylase inhibitor I13 was assessed for its effect on chronic myeloid leukemia (CML) cells harboring T315I-mutated and wild-type BCR-ABL. I13 showed strong activity against both types of cells, inducing cell differentiation and suppressing proliferation by causing cell cycle G0/G1-phase accumulation. It was found that I13 blocked the CML signaling pathway by depleting BCR-ABL, resulting in cell differentiation. These findings highlight I13 as a BCR-ABL modulator for overcoming drug resistance caused by T315I-mutated BCR-ABL and have implications for CML therapy development.

FRONTIERS IN PHARMACOLOGY (2023)

添加到收藏夹

Article Oncology

Case Report: The Formation of a Truncated PAX5 Transcript in a Case of Ph-Positive Mixed Phenotype Acute Leukemia With dic(7;9)(p11-p13;p13)

Yan Yu, Zhao Zeng, Jundan Xie, Qiongyu Lu, Wenzhi Cai, Ruixi Zhang, Jinlan Pan, Yun Zhao, Aining Sun, Huiying Qiu, Suning Chen

Summary: The PAX5-UBE2D4 fusion gene identified in a case of Ph-positive mixed phenotype acute leukemia has partial oncogenic activity, promoting tumor growth and cell proliferation.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Plant Sciences

Sphagneticola Trilobata (L.) Pruski (Asteraceae) Methanol Extract Induces Apoptosis in Leukemia Cells through Suppression of BCR/ABL

Hoang Thanh Chi, Nguyen Thi Lien Thuong, Bui Thi Kim Ly

Summary: The study found that the methanol extract of Sphagneticola trilobata (L.) Pruski (MeST) has an inhibitory effect on the growth of leukemia cells, especially those harboring imatinib-resistant BCR/ABL. The cell death induced by MeST is through apoptosis and it can also suppress the expression of the BCR/ABL protein.

PLANTS-BASEL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors

Yosuke Tanaka, Reina Takeda, Tsuyoshi Fukushima, Keiko Mikami, Shun Tsuchiya, Moe Tamura, Keito Adachi, Terumasa Umemoto, Shuhei Asada, Naoki Watanabe, Soji Morishita, Misa Imai, Masayoshi Nagata, Marito Araki, Hitoshi Takizawa, Tomofusa Fukuyama, Chrystelle Lamagna, Esteban S. Masuda, Ryoji Ito, Susumu Goyama, Norio Komatsu, Tomoiku Takaku, Toshio Kitamura

Summary: Leukemia stem cells in chronic myeloid leukemia are resistant to imatinib, but can be eliminated by combining imatinib with IRAK1/4 inhibitors that inhibit the IRAK1/4-NF-kappa B-PD-L1 signaling pathway.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Computational Identification of BCR-ABL Oncogenic Signaling as a Candidate Target of Withaferin A and Withanone

Vidhi Malik, Navaneethan Radhakrishnan, Sunil C. Kaul, Renu Wadhwa, Durai Sundar

Summary: The study suggests that Withaferin-A and Withanone from Ashwagandha have potential as natural drugs for the treatment of Chronic Myeloid Leukemia. These compounds interact with the protein kinase ABL, and inhibition of ABL may contribute to their anticancer activity.

BIOMOLECULES (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

Kill Two Birds with One Stone: A Multifunctional Dual-Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome-Positive Leukemia

Bohan Ma, Hui Feng, Chao Feng, Yi Liu, Hailing Zhang, Jincheng Wang, Wenjuan Wang, Pengcheng He, Fan Niu

Summary: The study designed a dual-targeting proteolysis-targeting chimera (PROTAC) type drug that can induce Bcr/Abl degradation and activate the p53 pathway simultaneously, potentially overcoming drug resistance in Ph+ leukemias.

ADVANCED SCIENCE (2022)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

Unlocking the secrets to Janus kinase activation

Ross L. Levine, Stevan R. Hubbard

SCIENCE (2022)

添加到收藏夹

Review Oncology

Isolation, Maintenance and Expansion of Adult Hematopoietic Stem/Progenitor Cells and Leukemic Stem Cells

Isabella Maria Mayer, Andrea Hoelbl-Kovacic, Veronika Sexl, Eszter Doma

Summary: Transplantation of adult hematopoietic stem cells is crucial for treating hematological disorders, while leukemic stem cells play a significant role in disease initiation and relapse. Understanding methods to maintain and expand hematopoietic cells, as well as isolate and enrich hematopoietic stem cells and leukemic stem cells, is essential for developing therapeutic strategies.

CANCERS (2022)

添加到收藏夹

Article Hematology

Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia

Maximilian Stahl, Andriy Derkach, Noushin Farnoud, Jan Philipp Bewersdorf, Troy Robinson, Christopher Famulare, Christina Cho, Sean Devlin, Kamal Menghrajani, Minal A. Patel, Sheng F. Cai, Linde A. Miles, Robert L. Bowman, Mark B. Geyer, Andrew Dunbar, Zachary D. Epstein-Peterson, Erin McGovern, Jessica Schulman, Jacob L. Glass, Justin Taylor, Aaron D. Viny, Eytan M. Stein, Bartlomiej Getta, Maria E. Arcila, Qi Gao, Juliet Barker, Brian C. Shaffer, Esperanza B. Papadopoulos, Boglarka Gyurkocza, Miguel-Angel Perales, Omar Abdel-Wahab, Ross L. Levine, Sergio A. Giralt, Yanming Zhang, Wenbin Xiao, Nidhi Pai, Elli Papaemmanuil, Martin S. Tallman, Mikhail Roshal, Aaron D. Goldberg

Summary: Measurable residual disease (MRD) is a powerful prognostic factor in acute myeloid leukemia (AML). This study aims to identify pre-treatment molecular predictors of immunophenotypic MRD clearance in AML patients. The results showed that induction chemotherapy led to different MRD responses, with 35% achieving MRD- remission, 27% achieving MRD+ remission, and 38% having persistent disease. Subsequent therapy resulted in MRD conversion in 34% of MRD+ patients and 26% of patients with persistent disease. Specific gene mutations and karyotypic abnormalities were found to be associated with high or low rates of MRD- remission. Patients with fewer individual clones were more likely to achieve MRD- remission. Furthermore, the study demonstrated that achieving MRD- prior to allogeneic stem cell transplant (allo-SCT) was associated with favorable outcomes. Therefore, the inclusion of patients with specific baseline mutational patterns and high clone numbers in clinical trials should be considered.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

添加到收藏夹

Article Hematology

SBNO2 is a critical mediator of STAT3-driven hematological malignancies

Tania Brandstoetter, Johannes Schmoellerl, Reinhard Grausenburger, Sebastian Kollmann, Eszter Doma, Jani Huuhtanen, Thorsten Klampfl, Thomas Eder, Florian Grebien, Gregor Hoermann, Johannes Zuber, Satu Mustjoki, Barbara Maurer, Veronika Sexl

Summary: Gain-of-function mutations in the STAT3 gene are frequently found in patients with LGLL, NK/T-cell leukemia, and adult T-cell leukemia/lymphoma. Murine hematopoietic stem and progenitor cell models expressing mutated STAT3Y640F showed increased proliferation and self-renewal potential. Through gene expression analysis and chromatin occupancy profiling, a conserved set of direct transcriptional targets of STAT3Y640F, including SBNO2, was identified. The STAT3-SBNO2 axis is also present in other STAT3-driven hematopoietic malignancies, suggesting SBNO2 as a potential therapeutic target.

BLOOD (2023)

添加到收藏夹

Article Oncology

Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms

Lindsay M. Gurska, Rachel Okabe, Alexandra Schurer, Meng Maxine Tong, Mark Soto, Daniel Choi, Kristina Ames, Shira Glushakow-Smith, Allison Montoya, Ellen Tein, Linde A. Miles, Haiying Cheng, Pamela Hankey-Giblin, Ross L. Levine, Swati Goel, Balazs Halmos, Kira Gritsman

Summary: The study found that crizotinib could suppress the activation of the JAK/STAT signaling pathway and decrease the disease burden of MPN. Additionally, crizotinib could overcome the persistence of JAK inhibitors by disrupting the interaction between RON kinase and JAK2. This research suggests that crizotinib should be further explored as a potential treatment for patients with MPN.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells

Jerome Fortin, Ming-Feng Chiang, Cem Meydan, Jonathan Foox, Parameswaran Ramachandran, Julie Leca, Francois Lemonnier, Wanda Y. Li, Miki S. Gams, Takashi Sakamoto, Mandy Chu, Chantal Tobin, Eric Laugesen, Troy M. Robinson, Annick You-Ten, Daniel J. Butler, Thorsten Berger, Mark D. Minden, Ross L. Levine, Cynthia J. Guidos, Ari M. Melnick, Christopher E. Mason, Tak W. Maka

Summary: Mutations in IDH1, IDH2, and TET2 genes are commonly observed in myeloid neoplasms. These mutations have unexpected, distinct effects on hematopoietic stem and progenitor cells, contrary to previous expectations. Understanding these molecular alterations could lead to the development of more effective, genotype-specific therapies.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

添加到收藏夹

Editorial Material Oncology

Oncogenic IDH1 Mutation Imparts Therapeutically Targetable Metabolic Dysfunction in Multiple Tumor Types

Troy M. Robinson, Ross L. Levine

Summary: In this study, the researchers used mass spectrometry metabolomics, stable isotope labeling, and functional studies to investigate metabolic vulnerabilities in cancers with mutations in isocitrate dehydrogenase (IDH). They provide compelling evidence that dysregulated lipid synthesis is a synthetic lethal target in cancers with IDH1 mutations, but not IDH2 mutations.

CANCER DISCOVERY (2023)

添加到收藏夹

Article Hematology

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Andrew J. Dunbar, Dongjoo Kim, Min Lu, Mirko Farina, Robert L. Bowman, Julie L. Yang, Young Park, Abdul Karzai, Wenbin Xiao, Zach Zaroogian, Kavi O'Connor, Shoron Mowla, Francesca Gobbo, Paola Verachi, Fabrizio Martelli, Giuseppe Sarli, Lijuan Xia, Nada Elmansy, Maria Kleppe, Zhuo Chen, Yang Xiao, Erin McGovern, Jenna Snyder, Aishwarya Krishnan, Corrine Hill, Keith Cordner, Anouar Zouak, Mohamed E. Salama, Jayden Yohai, Eric Tucker, Jonathan Chen, Jing Zhou, Timothy McConnell, Anna R. Migliaccio, Richard Koche, Raajit Rampal, Rong Fan, Ross L. Levine, Ronald Hoffman

Summary: Inflammatory signaling is crucial in the development of myelofibrosis (MF), a type of cancer. Recent studies have identified the involvement of JAK/STAT and NF-kappa B signaling in MF progression. This study further explores the role of CXCL8/CXCR2 signaling in MF pathogenesis, and highlights its potential as a therapeutic target.

BLOOD (2023)

添加到收藏夹

Article Oncology

Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis

James M. Foran, Zhuoxin Sun, Catherine Lai, Hugo F. Fernandez, Larry D. Cripe, Rhett P. Ketterling, Janis Racevskis, Selina M. Luger, Elisabeth Paietta, Hillard M. Lazarus, Yanming Zhang, John M. Bennett, Ross L. Levine, Jacob M. Rowe, Mark R. Litzow, Martin S. Tallman

Summary: This study examined the association of obesity with AML and its impact on clinical outcomes. The results showed that obesity was associated with certain clinical and genetic features of AML, but did not affect patient survival.

CANCER (2023)

添加到收藏夹

Article Oncology

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

Vu H. Duong, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Ronan T. Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J. Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Michael M. Boyiadzis

Summary: This study evaluated the efficacy of entospletinib, an oral inhibitor of spleen tyrosine kinase, combined with decitabine in patients with acute myeloid leukemia (AML) who have poor prognosis. The combination showed some activity and acceptable tolerance, but the complete remission rates were low and overall survival was short.

CANCER (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study

Laura Boucai, Ryan N. Ptashkin, Ross L. Levine, James A. Fagin

Summary: In this prospective cohort study, the effects of therapeutic radioactive iodine (RAI) on clonal hematopoiesis (CH) were examined. The results showed no increase in CH in patients treated with RAI over a 2-year follow-up period. It was also found that the presence of CH was associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.

CLINICAL ENDOCRINOLOGY (2023)

添加到收藏夹

Article Multidisciplinary Sciences

MEN1 mutations mediate clinical resistance to menin inhibition

Florian Perner, Eytan M. M. Stein, Daniela V. V. Wenge, Sukrit Singh, Jeonghyeon Kim, Athina Apazidis, Homa Rahnamoun, Disha Anand, Christian Marinaccio, Charlie Hatton, Yanhe Wen, Richard M. M. Stone, David Schaller, Shoron Mowla, Wenbin Xiao, Holly A. A. Gamlen, Aaron J. J. Stonestrom, Sonali Persaud, Elizabeth Ener, Jevon A. A. Cutler, John G. G. Doench, Gerard M. M. McGeehan, Andrea Volkamer, John D. D. Chodera, Radoslaw P. Nowak, Eric S. S. Fischer, Ross L. L. Levine, Scott A. A. Armstrong, Sheng F. F. Cai

Summary: Chromatin-binding proteins are important regulators of cell state in haematopoiesis. Clinical trials have shown that the menin inhibitor revumenib can treat leukaemia with KMT2Ar or NPM1 mutations. However, acquired resistance to menin inhibition may be caused by somatic mutations in the MEN1 gene.

NATURE (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Clonal hematopoiesis, aging and Alzheimer's disease

Pablo Sanchez Vela, Jennifer J. J. Trowbridge, Ross L. L. Levine

Summary: New data reveals the surprising association between clonal hematopoiesis and protection from Alzheimer's disease, highlighting the need for future studies to unravel the complex mechanisms underlying the role of clonal hematopoiesis in tissue-disease contexts and aging-associated diseases.

NATURE MEDICINE (2023)

添加到收藏夹

Article Hematology

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage

Umeshkumar Vekariya, Monika Toma, Margaret Nieborowska-Skorska, Bac Viet Le, Marie-Christine Caron, Anna-Mariya Kukuyan, Katherine Sullivan-Reed, Paulina Podszywalow-Bartnicka, Kumaraswamy N. Chitrala, Jessica Atkins, Malgorzata Drzewiecka, Wanjuan Feng, Joe Chan, Srinivas Chatla, Konstantin Golovine, Jaroslav Jelinek, Tomasz Sliwinski, Jayashri Ghosh, Ksenia Matlawska-Wasowska, Gurushankar Chandramouly, Reza Nejati, Mariusz Wasik, Stephen M. Sykes, Katarzyna Piwocka, Emir Hadzijusufovic, Peter Valent, Richard T. Pomerantz, George Morton, Wayne Childers, Huaqing Zhao, Elisabeth M. Paietta, Ross L. Levine, Martin S. Tallman, Hugo F. Fernandez, Mark R. Litzow, Gaorav P. Gupta, Jean-Yves Masson, Tomasz Skorski

Summary: Leukemia cells accumulate DNA damage, but altered DNA repair mechanisms protect them from apoptosis. Formaldehyde generated by serine/1-carbon cycle metabolism contributes to the accumulation of toxic DNA-protein crosslinks (DPCs) in leukemia cells. Oncogenic tyrosine kinases (OTKs) enhance the expression of DNA polymerase theta (POL theta) to repair DPC-containing DNA double-strand breaks. Inhibition of POL theta can be an effective therapeutic strategy for leukemia.

BLOOD (2023)

添加到收藏夹

Review Oncology

Cellular Plasticity in Mammary Gland Development and Breast Cancer

Madison N. Wicker, Kay-Uwe Wagner

Summary: Cellular plasticity, the ability of cells to change their identity, plays a crucial role in mammary gland development and breast cancer progression. This review provides a comprehensive overview of the factors and mechanisms that promote cellular plasticity in the mammary gland. It discusses changes in cell identity during normal development, the role of the gestation cycle, and highlights the importance of the microenvironment and extracellular matrix. The review also explores cellular reprogramming during mammary tumorigenesis, focusing on the origin of basal-like breast cancers and the role of oncogenic signaling networks. Additionally, recent advances in genetically engineered models to study cellular plasticity in vivo are discussed.

CANCERS (2023)

添加到收藏夹

暂无数据

Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2

期刊

出版社

NATURE PUBLISHING GROUP

关键词

类别

资金

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

评论

主要评分

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

推荐

导出引文

分享论文